This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefROBOTICS

Human-Machine Symbiosis Exoskeleton System SymbiLimb Receives FDA Approval: Amputee Patients Feel Prosthetic Touch for the First Time

SymbiLimb, developed jointly by Johns Hopkins University and Ossur, receives FDA approval, using neural interfaces to transmit tactile signals from prosthetics directly back to patients' brains, achieving true human-machine symbiosis.

Human-Machine Symbiosis Exoskeleton System SymbiLimb Receives FDA Approval: Amputee Patients Feel Prosthetic Touch for the First Time

SymbiLimb, a human-machine symbiosis exoskeleton system jointly developed by Johns Hopkins University Applied Physics Laboratory and Icelandic prosthetics company Ossur, received FDA approval on August 26, 2030. Through an implanted neural interface, the system transmits pressure, temperature, and vibration signals from the prosthetic hand directly to the patient's residual limb nerves, enabling amputees to "feel" the authentic tactile sensation of their prosthetic touching objects for the first time.

SymbiLimb's core technology is the "bidirectional neural interface." Traditional smart prosthetics only achieve a one-way channel from brain to prosthetic for motor control. SymbiLimb integrates 128 micro-sensors at the prosthetic fingertips, converting tactile signals into electrical pulses transmitted back to the brain through a microelectrode array implanted in the residual limb's nerve bundle.

In clinical trials, 15 forearm amputee patients completed fine manipulation tasks using SymbiLimb. In a blindfolded object material identification test, patients achieved 94% accuracy, approaching the 97% of intact human hands. More importantly, patients reported that using SymbiLimb felt as if the prosthetic was "part of their own body" rather than an external tool.

Johns Hopkins University neuroengineering professor Sliman Bensmaia said: "SymbiLimb achieves the ultimate goal of prosthetic technology — making the prosthetic a natural extension of the body. The moment patients could feel their prosthetic touching objects, their emotional reaction was very powerful."

SymbiLimb's initial indication is for forearm amputees. Ossur plans to expand indications to upper arm and lower limb amputees by 2031. The system is priced at $150,000, and multiple insurance companies have expressed willingness to include it in coverage.